NasdaqGS - Delayed Quote USD

Codexis, Inc. (CDXS)

2.6600 +0.0100 (+0.38%)
At close: 4:00 PM EDT
2.6600 0.00 (0.00%)
After hours: 4:20 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
70,143.0000
70,143.0000
138,590.0000
104,754.0000
69,056.0000
Cost of Revenue
12,809.0000
12,809.0000
38,033.0000
22,209.0000
13,742.0000
Gross Profit
57,334.0000
57,334.0000
100,557.0000
82,545.0000
55,314.0000
Operating Expense
112,135.0000
112,135.0000
132,271.0000
105,242.0000
79,234.0000
Operating Income
-54,801.0000
-54,801.0000
-31,714.0000
-22,697.0000
-23,920.0000
Net Non Operating Interest Income Expense
4,172.0000
4,172.0000
1,441.0000
459.0000
405.0000
Other Income Expense
-25,542.0000
-25,542.0000
-3,043.0000
1,148.0000
-156.0000
Pretax Income
-76,171.0000
-76,171.0000
-33,316.0000
-21,090.0000
-23,671.0000
Tax Provision
69.0000
69.0000
276.0000
189.0000
339.0000
Net Income Common Stockholders
-76,240.0000
-76,240.0000
-33,592.0000
-21,279.0000
-24,010.0000
Diluted NI Available to Com Stockholders
-76,240.0000
-76,240.0000
-33,592.0000
-21,279.0000
-24,010.0000
Basic EPS
-1.12
--
-0.51
-0.33
-0.40
Diluted EPS
-1.12
--
-0.51
-0.33
-0.40
Basic Average Shares
68,131.0000
--
65,344.0000
64,568.0000
59,360.0000
Diluted Average Shares
68,131.0000
--
65,344.0000
64,568.0000
59,360.0000
Total Operating Income as Reported
-68,069.0000
-68,069.0000
-34,881.0000
-22,697.0000
-23,920.0000
Total Expenses
124,944.0000
124,944.0000
170,304.0000
127,451.0000
92,976.0000
Net Income from Continuing & Discontinued Operation
-76,240.0000
-76,240.0000
-33,592.0000
-21,279.0000
-24,010.0000
Normalized Income
-65,758.2800
-65,758.2800
-31,090.0700
-21,279.0000
-24,010.0000
Interest Income
4,172.0000
4,172.0000
1,441.0000
459.0000
405.0000
Net Interest Income
4,172.0000
4,172.0000
1,441.0000
459.0000
405.0000
EBIT
-54,801.0000
-54,801.0000
-31,714.0000
-22,697.0000
-23,920.0000
EBITDA
-44,878.0000
-44,878.0000
-21,463.0000
-16,750.0000
-19,366.0000
Reconciled Cost of Revenue
12,809.0000
12,809.0000
38,033.0000
22,209.0000
13,742.0000
Reconciled Depreciation
9,923.0000
9,923.0000
10,251.0000
5,947.0000
4,554.0000
Net Income from Continuing Operation Net Minority Interest
-76,240.0000
-76,240.0000
-33,592.0000
-21,279.0000
-24,010.0000
Total Unusual Items Excluding Goodwill
-13,268.0000
-13,268.0000
-3,167.0000
--
--
Total Unusual Items
-13,268.0000
-13,268.0000
-3,167.0000
--
--
Normalized EBITDA
-31,610.0000
-31,610.0000
-18,296.0000
-16,750.0000
-19,366.0000
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0003
0.0003
Tax Effect of Unusual Items
-2,786.2800
-2,786.2800
-665.0700
--
--
12/31/2020 - 4/22/2010

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

NRXP NRx Pharmaceuticals, Inc.
3.5400
+12.74%
 
CRBU Caribou Biosciences, Inc.
3.7100
-1.33%
 
TSHA Taysha Gene Therapies, Inc.
2.3900
+3.91%
 
EYEN Eyenovia, Inc.
0.6282
-11.68%
 
PRQR ProQR Therapeutics N.V.
1.9400
-1.02%
 
CDTX Cidara Therapeutics, Inc.
12.63
-2.85%
 
PTN Palatin Technologies, Inc.
1.8200
+5.81%
 
CLRB Cellectar Biosciences, Inc.
3.0300
+0.33%
 
WVE Wave Life Sciences Ltd.
4.6600
-1.69%
 
GALT Galectin Therapeutics Inc.
3.4500
-1.43%